Lean Six Sigma as a Management Tool Helps Standardize Antimicrobial Use in Hospital Settings.

IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL
Drug Design, Development and Therapy Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S510926
Qian Wang, Xinru Han, Xiang Zhang, Lubo Guo
{"title":"Lean Six Sigma as a Management Tool Helps Standardize Antimicrobial Use in Hospital Settings.","authors":"Qian Wang, Xinru Han, Xiang Zhang, Lubo Guo","doi":"10.2147/DDDT.S510926","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to standardize antimicrobial use in a hospital setting by implementing the Lean Six Sigma (LSS)-DMAIC model (Define, Measure, Analyze, Improve, Control), addressing the irrational use of antibacterial drugs.</p><p><strong>Methods: </strong>A retrospective analysis was conducted using data from a single hospital's information system in Shandong, China, covering antibacterial drug usage from January 2020 to December 2021. The LSS-DMAIC framework was applied, which involved defining problems, measuring key indicators, analyzing causes of irrational use, implementing improvement measures, and controlling outcomes. The project team comprised clinical pharmacists and healthcare professionals who evaluated antibiotic use and compliance with guidelines.</p><p><strong>Results: </strong>In the whole hospital, the management through LSS-DMAIC led to a significant reduction in the non-standard utilization rate of antibacterial drugs from 32.5% to 11.3% (P < 0.0001), achieving the set target. The intensity of antibacterial drug use decreased to 38.82 Defined Daily Doses (DDDs), meeting national standards. Additionally, the utilization rate of antibacterial drugs has dropped from 43.61% to 40.16% (P < 0.0001), and the average cost of antibacterial drugs per inpatient significantly dropped from 1909.59 RMB (known as Renminbi, which is the legal currency of China) to 1675.20 RMB (P < 0.0001), resulting in substantial annual savings.</p><p><strong>Conclusion: </strong>The application of the LSS-DMAIC model effectively improved the rational use of antibacterial drugs in the hospital, demonstrating its potential as a valuable management tool in healthcare settings. Continued efforts are necessary to sustain these improvements and further enhance clinician adherence to antimicrobial stewardship practices.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"3539-3554"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050037/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S510926","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to standardize antimicrobial use in a hospital setting by implementing the Lean Six Sigma (LSS)-DMAIC model (Define, Measure, Analyze, Improve, Control), addressing the irrational use of antibacterial drugs.

Methods: A retrospective analysis was conducted using data from a single hospital's information system in Shandong, China, covering antibacterial drug usage from January 2020 to December 2021. The LSS-DMAIC framework was applied, which involved defining problems, measuring key indicators, analyzing causes of irrational use, implementing improvement measures, and controlling outcomes. The project team comprised clinical pharmacists and healthcare professionals who evaluated antibiotic use and compliance with guidelines.

Results: In the whole hospital, the management through LSS-DMAIC led to a significant reduction in the non-standard utilization rate of antibacterial drugs from 32.5% to 11.3% (P < 0.0001), achieving the set target. The intensity of antibacterial drug use decreased to 38.82 Defined Daily Doses (DDDs), meeting national standards. Additionally, the utilization rate of antibacterial drugs has dropped from 43.61% to 40.16% (P < 0.0001), and the average cost of antibacterial drugs per inpatient significantly dropped from 1909.59 RMB (known as Renminbi, which is the legal currency of China) to 1675.20 RMB (P < 0.0001), resulting in substantial annual savings.

Conclusion: The application of the LSS-DMAIC model effectively improved the rational use of antibacterial drugs in the hospital, demonstrating its potential as a valuable management tool in healthcare settings. Continued efforts are necessary to sustain these improvements and further enhance clinician adherence to antimicrobial stewardship practices.

精益六西格玛作为管理工具有助于规范医院环境中的抗菌药物使用。
目的:通过实施精益六西格玛(LSS)-DMAIC模型(定义、测量、分析、改进、控制),规范医院抗菌药物使用,解决抗菌药物不合理使用问题。方法:对山东省某医院信息系统2020年1月至2021年12月抗菌药物使用情况进行回顾性分析。采用LSS-DMAIC框架,定义问题,衡量关键指标,分析不合理使用原因,实施改进措施,控制结果。项目小组由临床药剂师和医疗保健专业人员组成,他们评估抗生素的使用和对指南的遵守情况。结果:全院通过LSS-DMAIC管理,抗菌药物非标准使用率由32.5%显著降低至11.3% (P < 0.0001),达到了既定目标。抗菌药物使用强度降至38.82限定日剂量(DDDs),符合国家标准。抗菌药物使用率从43.61%下降到40.16% (P < 0.0001),住院患者人均抗菌药物费用从1909.59元(人民币,中国法定货币)显著下降到1675.20元(P < 0.0001),每年节省大量费用。结论:LSS-DMAIC模型的应用有效地促进了医院抗菌药物的合理使用,显示了其作为医疗卫生机构有价值的管理工具的潜力。需要继续努力维持这些改进,并进一步加强临床医生对抗菌药物管理实践的遵守。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Design, Development and Therapy
Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY
CiteScore
9.00
自引率
0.00%
发文量
382
审稿时长
>12 weeks
期刊介绍: Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信